INM
InMedยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
INM Profile
Inmed Pharmaceuticals Inc.
A leader in the research, development and manufacturing of rare cannabinoids
Suite 1445, 885 West Georgia St., Vancouver, British, Columbia, Canada V6C 3E8
--
InMed Pharmaceuticals Inc., was incorporated in British Columbia on May 19, 1981 under the British Columbia Business Companies Act. The Company is a pharmaceutical company that is developing a series of proprietary small molecule drug candidates that are priority signaling ligands for endogenous CB1 and CB2 receptors, as well as other receptor targets associated with human diseases. Through its R&D efforts, the company focuses on therapeutic areas with unmet medical needs, and its projects involve diseases such as Alzheimer's disease, dry age-related macular degeneration and epidermolysis bullosa. Together with its wholly-owned subsidiary BayMedica, LLC, InMed also develops proprietary manufacturing methods to produce and commercialize bulk rare cannabinoids as ingredients in multiple market segments, thereby maintaining its position in pharmaceutical innovation and cannabinoid-based technologies.
